Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 15.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,965 shares of the biopharmaceutical company’s stock after selling 3,656 shares during the period. ProShare Advisors LLC’s holdings in Intra-Cellular Therapies were worth $1,367,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Oak Ridge Investments LLC acquired a new position in shares of Intra-Cellular Therapies during the second quarter valued at $811,000. Perceptive Advisors LLC acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at $7,735,000. SG Americas Securities LLC increased its holdings in shares of Intra-Cellular Therapies by 962.7% during the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after purchasing an additional 44,188 shares during the period. Schroder Investment Management Group increased its holdings in shares of Intra-Cellular Therapies by 36.7% during the fourth quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock valued at $55,851,000 after purchasing an additional 209,331 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in Intra-Cellular Therapies by 12.3% during the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after buying an additional 191,416 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on ITCI. Mizuho raised their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, June 21st. UBS Group decreased their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. The Goldman Sachs Group decreased their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada decreased their target price on Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their target price for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.58.

Insider Activity

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $77,962,764.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The disclosure for this sale can be found here. Insiders have sold a total of 175,316 shares of company stock worth $13,037,345 in the last ninety days. Corporate insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.1 %

Shares of NASDAQ ITCI opened at $73.30 on Friday. Intra-Cellular Therapies, Inc. has a one year low of $45.50 and a one year high of $84.89. The firm has a market capitalization of $7.74 billion, a PE ratio of -63.19 and a beta of 1.00. The business has a 50-day moving average price of $75.47 and a two-hundred day moving average price of $71.66.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The firm had revenue of $161.40 million during the quarter, compared to analyst estimates of $157.74 million. During the same period last year, the company posted ($0.45) EPS. The business’s quarterly revenue was up 45.7% compared to the same quarter last year. Research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.